<DOC>
	<DOCNO>NCT02193217</DOCNO>
	<brief_summary>The purpose study explore cardiac pharmacodynamics , safety tolerability MT-1303 healthy subject .</brief_summary>
	<brief_title>A Phase 1 Study Explore Cardiac Pharmacodynamics MT-1303</brief_title>
	<detailed_description />
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Fingolimod Hydrochloride</mesh_term>
	<criteria>Healthy free clinically significant illness disease . Male female subject nonchildbearing potential age 18 55 year . Normal nonclinically significant 12lead ECG . Holter record clinically significant abnormality . Systolic blood pressure : 90 140 mmHg , diastolic blood pressure : 50 90 mmHg A History severe adverse reaction allergy medical product . Clinically significant endocrine , thyroid , hepatic , respiratory , gastrointestinal , renal , cardiovascular disease , eye disorder history psychiatric/psychotic disorder . A history tuberculosis . Have positive HBsAg , HBcAb , HCVAb HIV1 HIV2 test . Previously receive MT1303 , fingolimod , sphingosine1phosphate receptor modulators . Clinical relevant abnormal medical history , physical finding laboratory value . Clinically significant 12lead ECG abnormality . Clinical relevant abnormal finding echocardiograph .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>